In a high-stakes clash within the pharmaceutical industry, Novo Nordisk’s attempt to disrupt Pfizer’s acquisition of weight-loss biotech Metsera is facing significant challenges. The U.S. pharmaceutical giant has escalated the tensions by filing a lawsuit against both Novo and Metsera in a Delaware court, claiming that Novo’s unsolicited bid constitutes an illegal interference intended to undermine its takeover.
The battle intensified following the U.S. Federal Trade Commission’s (FTC) unexpected green light for Pfizer’s acquisition deal, which was valued at up to $7.3 billion. This approval is particularly notable given the current government shutdown and signals the FTC’s awareness and interest in the unfolding corporate drama. With the administration’s recent measures supporting national interests in corporate takeovers, insiders suggest that the Trump administration might lend favor to Pfizer’s cause, viewing it as a strategic opportunity in the competitive obesity drug market.
Novo recently launched a bid for Metsera worth around $9 billion, claiming it to be a “superior” offer. However, Pfizer quickly countered with accusations of market manipulation, arguing that Novo’s structure is designed to dodge antitrust scrutiny. The lawsuit from Pfizer characterized Novo’s proposal as “an old-fashioned bribe” aimed at swaying Metsera’s board and key shareholders against Pfizer’s interests. As part of its claim, Pfizer seeks to pause Novo’s bid and recover damages, asserting that the proposed takeover violates competition laws.
Novo’s unusual two-part payment strategy, which includes an upfront payment of $6.5 billion, has come under scrutiny. Pfizer’s leadership argues that such tactics are indicative of Novo’s dominant position in the weight-loss drug market and are specifically crafted to avoid regulatory obstacles. Novo’s competitive positioning has been challenged recently as it tries to catch up with rivals like Eli Lilly in the lucrative weight-loss sector.
Meanwhile, Pfizer is keen to secure a foothold in the obesity market, particularly after a failed clinical trial of an in-house weight-loss drug earlier this year. Metsera is currently engaged in four clinical trials for obesity drugs, putting it in a robust position compared to existing treatments.
Following the FTC’s approval of Pfizer’s deal, which occurred ahead of a critical November deadline, Pfizer issued a statement highlighting this significant regulatory clearance. Despite the government shutdown affecting many processes, an exception was made for Pfizer-Metsera, bolstering its case.
Responding to Pfizer’s allegations, Novo firmly stated that they believe the claims are without merit and expressed confidence in their legal position. Metsera, for its part, has also expressed disagreement with Pfizer’s assertions and is prepared to contest the claims in court.
Industry analysts note that this dispute reflects just how contentious mergers and acquisitions have become in the biopharmaceutical sector. With rising tensions and heightened rhetoric, the unfolding saga between Pfizer and Novo is being closely watched, particularly given the potential implications for market dynamics in the rapidly evolving field of weight-loss treatments.
In terms of market response, Pfizer’s shares saw a rise of 1.4 percent following the news, while Metsera’s shares dropped by 1.1 percent amid the escalating conflict. Observers expect this competitive drama to continue reshaping the pharmaceutical landscape as both companies pursue their objectives in an industry marked by rapidly changing dynamics.
